🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Shraddha Rastogi

National Cancer Institute

ORCID: 0000-0003-0680-0407

Also affiliated with Center for Cancer Research

MedicineNeuroscienceAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma”.

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

The Oncologist(2023)10.1093/oncolo/oyad164
N/A
0.512DataRank · unranked
12 citations

Yoshimi Endo Greer, Sarah M. Jenkins, Margaret E. Gatti‐Mays, Nicole Houston, Sunmin Lee +11 more

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in Oncology(2024)10.3389/fonc.2024.1386190
N/A
0.421DataRank · unranked
9 citations

Cody J. Peer, Xianyu Zhang, Hyoyoung Choo‐Wosoba, Mehwish Ahmad, Min-Jung Lee +13 more

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Cancer Medicine(2025)10.1002/cam4.71220
N/A
0.104DataRank · unranked
1 citations

Ashley Cimino‐Mathews, Stanley Lipkowitz, Min-Jung Lee, Jayakumar R. Nair, B. Brooke Solarz +9 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6
N/A
0DataRank · unranked
42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Topoisomerase III-beta protects from immune dysregulation and tumorigenesis

Science Advances(2025)10.1126/sciadv.ady7028
N/A
0DataRank · unranked
2 citations

Simone A. Baechler, Anjali Dhall, Sourav Saha, Hongliang Zhang, Laura Bassel +11 more

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3051
N/A
0DataRank · unranked
4 citations

Mehwish Ahmad, Guillaume Joe Pegna, Cody J. Peer, Jane B. Trepel, Min-Jung Lee +9 more

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1
N/A
0DataRank · unranked
0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more

Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15017
N/A
0DataRank · unranked
1 citations

Cody J. Peer, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Shraddha Rastogi +10 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1
N/A
0DataRank · unranked
0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more